Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Home-based Progressive Resistance Exercise to Enhance Physical Performance of Older Adults With Possible Sarcopenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04851262
Recruitment Status : Recruiting
First Posted : April 20, 2021
Last Update Posted : April 20, 2021
Sponsor:
Information provided by (Responsible Party):
Dr. Pui-Hing Chau, The University of Hong Kong

Brief Summary:
The overall aim of the proposed project is to improve muscle strength in older adults with possible sarcopenia by promoting home-based progressive resistance exercise. The target population for health talks is community-dwelling older adults. A Three monthly home-visits and weekly phone calls will be made. A waitlist randomised controlled trial will be conducted to evaluate effectiveness, and qualitative feedback will be collected from participants. A pilot study will be conducted first.

Condition or disease Intervention/treatment Phase
Sarcopenia Behavioral: Exercise Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Home-based Progressive Resistance Exercise to Enhance Physical Performance of Older Adults With Possible Sarcopenia
Estimated Study Start Date : April 2021
Estimated Primary Completion Date : April 2024
Estimated Study Completion Date : April 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Intervention
The intervention is a 12-week home-based resistance training programme with phased progression. The intervention will have three phases: (i) an initial phase focused on training the target muscle(s)/movements with minimal or no external weight; (ii) an intermediate phase targeting muscle strength with increased practice resistance; and (iii) an advanced phase targeting the further enhancement of muscle strength by challenging multiple muscle groups. Each phase will involve exercises targeting the trunk, back, hip, upper-limb and lower-limb muscles.
Behavioral: Exercise
The intervention is to be taught by fitness trainer at the participants' home at the start of each phase. The exercise progression model for older adults recommended by the American College of Sports Medicine, which emphasise gradual increments in training load and systematically alter one or more programme components, will be adopted.

Waitlist control
The waitlist control participants will start the intervention 12 weeks after the baseline assessment.
Behavioral: Exercise
The intervention is to be taught by fitness trainer at the participants' home at the start of each phase. The exercise progression model for older adults recommended by the American College of Sports Medicine, which emphasise gradual increments in training load and systematically alter one or more programme components, will be adopted.




Primary Outcome Measures :
  1. Change in lower-limb muscle strength at 12 weeks from baseline [ Time Frame: 12 weeks after baseline ]
    Measured by Short Physical Performance Battery (SPPB)


Secondary Outcome Measures :
  1. Change in lower-limb muscle strength at 24 weeks from baseline [ Time Frame: 24 weeks after baseline ]
    Measured by Short Physical Performance Battery (SPPB)


Other Outcome Measures:
  1. Change in handgrip strength at 12 weeks from baseline [ Time Frame: 12 weeks after baseline ]
    Measured by a spring-type dynamometer

  2. Change in handgrip strength at 24 weeks from baseline [ Time Frame: 24 weeks after baseline ]
    Measured by a spring-type dynamometer

  3. Status of possible sarcopenia at 12 weeks from baseline [ Time Frame: 12 weeks after baseline ]
    Indicated by 5-time chair stand test ≥12 second, or men and women with <28 kg and <18 kg strength

  4. Status of possible sarcopenia at 24 weeks from baseline [ Time Frame: 24 weeks after baseline ]
    Indicated by 5-time chair stand test ≥12 second, or men and women with <28 kg and <18 kg strength

  5. Sarcopenia risk score at 12 weeks from baseline [ Time Frame: 12 weeks after baseline ]
    Measured by SARC-CalF

  6. Sarcopenia risk score at 24weeks from baseline [ Time Frame: 24 weeks after baseline ]
    Measured by SARC-CalF



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years to 89 Years   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

The inclusion criteria are:

  • Aged 65-89;
  • Possible sarcopenia (defined by AWGS 2019);
  • No cognitive impairment (Abbreviated Mental Test score ≥8); and
  • No communication problems.

The exclusion criteria are:

  • having engaged in a structured exercise programme in the past 6 months or planning to do so within the intervention period;
  • mobility-limiting injury of the hands or lower limbs, surgery or hospitalisation within the intervention period;
  • contraindications such as musculoskeletal/cardiorespiratory disorders, or any advanced diseases that inhibit them from exercising.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04851262


Locations
Layout table for location information
Hong Kong
Community Recruiting
Hong Kong, Hong Kong
Contact: P Chau    39176626    phpchau@hku.hk   
Sponsors and Collaborators
The University of Hong Kong
Layout table for additonal information
Responsible Party: Dr. Pui-Hing Chau, Associate Professor, The University of Hong Kong
ClinicalTrials.gov Identifier: NCT04851262    
Other Study ID Numbers: UW20-868
First Posted: April 20, 2021    Key Record Dates
Last Update Posted: April 20, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: To protect confidentiality of participants.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Sarcopenia
Muscular Atrophy
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Atrophy
Pathological Conditions, Anatomical